Iceland· IS-EU/1/13/830/001-002

Stribild

A emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat product containing emtricitabinum inn,tenofovir disoproxil fumarate,elvitegravirum inn,cobicistatum inn, registered in Iceland by Gilead Sciences Ireland UC*. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR09

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedStribildATCJ05AR09REGISTER NO.IS-EU/1/13/830/001-002PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR09 (emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 8 of them publish a price we can compare per daily dose

Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat · ATC J05AR09

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Emtricitabinum INN,Tenofovir disoproxil fumarate,Elvitegravirum INN,Cobicistatum INN
Manufacturer
Gilead Sciences Ireland UC*
Country
Iceland (IS)
ATC code
J05AR09
ATC class
Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    168038
    30 stk x1 glas
    ISK 164583

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Stribild
  • Norway · Stribild

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/491553bf-2d75-458d-8943-ae64a6d9326e
GET /v1/drugs/491553bf-2d75-458d-8943-ae64a6d9326e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "J05AR09",
  "marketed": true,
  "strength": "150 mg/150 mg/200 mg/245 mg",
  "ma_number": "EU/1/13/830/001-002",
  "substance": "Emtricitabinum INN,Tenofovir disoproxil fumarate,Elvitegravirum INN,Cobicistatum INN",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í smitsjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "41418"
}

See everything about emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.